Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-06-18

AUTHORS

Akiko Matsui, Michihiro Morimoto, Hiroshi Suzuki, Thomas Laurent, Yoko Fujimoto, Yoshimi Inagaki

ABSTRACT

OBJECTIVES: To investigate changes in sedation practice during 2012-2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015. METHODS: Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine. RESULTS: DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures. CONCLUSION: The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change. More... »

PAGES

137-147

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y

DOI

http://dx.doi.org/10.1007/s40801-018-0136-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104878139

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29916196


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsui", 
        "givenName": "Akiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Michihiro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Hiroshi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laurent", 
        "givenName": "Thomas", 
        "id": "sg:person.0736342751.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736342751.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan", 
          "id": "http://www.grid.ac/institutes/grid.418567.9", 
          "name": [
            "Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujimoto", 
        "givenName": "Yoko", 
        "id": "sg:person.01216450244.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216450244.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan", 
          "id": "http://www.grid.ac/institutes/grid.265107.7", 
          "name": [
            "Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Inagaki", 
        "givenName": "Yoshimi", 
        "id": "sg:person.01257511361.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257511361.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/cc712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051258507", 
          "https://doi.org/10.1186/cc712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00134-002-1338-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002941822", 
          "https://doi.org/10.1007/s00134-002-1338-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-06-18", 
    "datePublishedReg": "2018-06-18", 
    "description": "OBJECTIVES: To investigate changes in sedation practice during 2012-2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015.\nMETHODS: Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine.\nRESULTS: DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures.\nCONCLUSION: The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40801-018-0136-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1051855", 
        "issn": [
          "2199-1154", 
          "2198-9788"
        ], 
        "name": "Drugs - Real World Outcomes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "keywords": [
      "sedative analgesic combination", 
      "catheter ablation", 
      "endoscopic examination", 
      "procedural sedation", 
      "local anesthesia", 
      "complication trends", 
      "large health claims database", 
      "Medical Data Vision Co.", 
      "incidence of complications", 
      "use of dexmedetomidine", 
      "health claims database", 
      "gastrointestinal endoscopic examination", 
      "occurrence of complications", 
      "retrospective database study", 
      "use of benzodiazepines", 
      "respiratory depression", 
      "common complication", 
      "general anesthesia", 
      "claims database", 
      "gastrointestinal endoscopy", 
      "sedation practices", 
      "dexmedetomidine", 
      "database study", 
      "clinical practice", 
      "propofol", 
      "endoscopic surgery", 
      "complications", 
      "sedation", 
      "anesthesia", 
      "midazolam", 
      "study period", 
      "utilization proportion", 
      "same day", 
      "surgery", 
      "sedatives", 
      "thiamylal", 
      "ablation", 
      "proportion", 
      "vomiting", 
      "nausea", 
      "bradycardia", 
      "patients", 
      "ketamine", 
      "endoscopy", 
      "diazepam", 
      "benzodiazepines", 
      "incidence", 
      "flunitrazepam", 
      "depression", 
      "combination patterns", 
      "database", 
      "examination", 
      "changes", 
      "days", 
      "practice", 
      "use", 
      "combination", 
      "ES", 
      "period", 
      "trends", 
      "records", 
      "study", 
      "occurrence", 
      "procedure", 
      "recent trends", 
      "patterns", 
      "utilization", 
      "Japan", 
      "order", 
      "Ltd.", 
      "Co.", 
      "sedative utilization", 
      "Data Vision Co.", 
      "Vision Co.", 
      "annual utilization proportions", 
      "proportion of DEX", 
      "sedative-analgesic combination patterns"
    ], 
    "name": "Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in Japan: A Retrospective Database Study in Clinical Practice from 2012 to 2015", 
    "pagination": "137-147", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104878139"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40801-018-0136-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29916196"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40801-018-0136-y", 
      "https://app.dimensions.ai/details/publication/pub.1104878139"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_766.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40801-018-0136-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40801-018-0136-y'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      22 PREDICATES      105 URIs      95 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40801-018-0136-y schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Nf194eba3b8cf403caa332cd24fe420dd
4 schema:citation sg:pub.10.1007/s00134-002-1338-y
5 sg:pub.10.1186/cc712
6 schema:datePublished 2018-06-18
7 schema:datePublishedReg 2018-06-18
8 schema:description OBJECTIVES: To investigate changes in sedation practice during 2012-2015, using a large health claims database, for catheter ablation (CA), gastrointestinal endoscopic examination (EE), and surgery (ES) after dexmedetomidine (DEX) was approved for procedural sedation in 2013. We assessed the trends of sedative utilization, sedative-analgesic combinations, and, additionally, incidence of complications from 2012 to 2015. METHODS: Using the database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan), annual utilization proportions of the sedatives and sedative-analgesic combinations and occurrence of complications were calculated in patients with a record of local anesthesia and CA, EE, and/or ES but without general anesthesia used on the same day. The sedatives studied were DEX, propofol (PF), midazolam (MDZ), diazepam, flunitrazepam, thiamylal (TIA), thiopental (TIO), and ketamine. RESULTS: DEX was used most often for CA, followed by PF. From 2012 to 2015, the proportion of DEX increased from 30 to 36%, and that of PF slightly decreased from 29 to 27%. The order of utilization proportions did not change for EE or ES. The use of benzodiazepines, particularly MDZ, predominated. The top five sedative-analgesic combination patterns changed during the study period for CA, but not for EE or ES. The most common complications with CA, EE, and ES were bradycardia, nausea and vomiting, and respiratory depression, respectively. There were no changes in the complications' trends for the procedures. CONCLUSION: The approved use of DEX for procedural sedation resulted in changes for CA, but not for EE or ES. The complication trends did not change.
9 schema:genre article
10 schema:inLanguage en
11 schema:isAccessibleForFree true
12 schema:isPartOf N26ac7ea362df475dae9b8fea6e8f05d8
13 N923a9f10dec94d7a82081922bb1ca9e4
14 sg:journal.1051855
15 schema:keywords Co.
16 Data Vision Co.
17 ES
18 Japan
19 Ltd.
20 Medical Data Vision Co.
21 Vision Co.
22 ablation
23 anesthesia
24 annual utilization proportions
25 benzodiazepines
26 bradycardia
27 catheter ablation
28 changes
29 claims database
30 clinical practice
31 combination
32 combination patterns
33 common complication
34 complication trends
35 complications
36 database
37 database study
38 days
39 depression
40 dexmedetomidine
41 diazepam
42 endoscopic examination
43 endoscopic surgery
44 endoscopy
45 examination
46 flunitrazepam
47 gastrointestinal endoscopic examination
48 gastrointestinal endoscopy
49 general anesthesia
50 health claims database
51 incidence
52 incidence of complications
53 ketamine
54 large health claims database
55 local anesthesia
56 midazolam
57 nausea
58 occurrence
59 occurrence of complications
60 order
61 patients
62 patterns
63 period
64 practice
65 procedural sedation
66 procedure
67 propofol
68 proportion
69 proportion of DEX
70 recent trends
71 records
72 respiratory depression
73 retrospective database study
74 same day
75 sedation
76 sedation practices
77 sedative analgesic combination
78 sedative utilization
79 sedative-analgesic combination patterns
80 sedatives
81 study
82 study period
83 surgery
84 thiamylal
85 trends
86 use
87 use of benzodiazepines
88 use of dexmedetomidine
89 utilization
90 utilization proportion
91 vomiting
92 schema:name Recent Trends in the Practice of Procedural Sedation Under Local Anesthesia for Catheter Ablation, Gastrointestinal Endoscopy, and Endoscopic Surgery in Japan: A Retrospective Database Study in Clinical Practice from 2012 to 2015
93 schema:pagination 137-147
94 schema:productId N37fecc389e0a415789a23ae62e5efec9
95 N3f0a99958e4b423e893495b00e1b7f76
96 N4c4668c350cd4218b90e52837ae930e8
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104878139
98 https://doi.org/10.1007/s40801-018-0136-y
99 schema:sdDatePublished 2022-01-01T18:47
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N9821d644d338422ba7f19de612dd060d
102 schema:url https://doi.org/10.1007/s40801-018-0136-y
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N1e253898ee91435aaa27584882508958 rdf:first N76f7211c54054990b5cfd44cd52f47a7
107 rdf:rest N3afcaa895bb24943a6e6787301f6e024
108 N26ac7ea362df475dae9b8fea6e8f05d8 schema:issueNumber 3
109 rdf:type schema:PublicationIssue
110 N37fecc389e0a415789a23ae62e5efec9 schema:name doi
111 schema:value 10.1007/s40801-018-0136-y
112 rdf:type schema:PropertyValue
113 N3afcaa895bb24943a6e6787301f6e024 rdf:first N659067dc0e764cfa92e2ded26c6c5430
114 rdf:rest Nf973524fc7ac4f08b290c7052d5c20a1
115 N3f0a99958e4b423e893495b00e1b7f76 schema:name dimensions_id
116 schema:value pub.1104878139
117 rdf:type schema:PropertyValue
118 N4c4668c350cd4218b90e52837ae930e8 schema:name pubmed_id
119 schema:value 29916196
120 rdf:type schema:PropertyValue
121 N5df8cba9a77c43b9b368dc9b4dfcc62a rdf:first sg:person.01257511361.01
122 rdf:rest rdf:nil
123 N659067dc0e764cfa92e2ded26c6c5430 schema:affiliation grid-institutes:grid.418567.9
124 schema:familyName Suzuki
125 schema:givenName Hiroshi
126 rdf:type schema:Person
127 N76f7211c54054990b5cfd44cd52f47a7 schema:affiliation grid-institutes:grid.418567.9
128 schema:familyName Morimoto
129 schema:givenName Michihiro
130 rdf:type schema:Person
131 N923a9f10dec94d7a82081922bb1ca9e4 schema:volumeNumber 5
132 rdf:type schema:PublicationVolume
133 N9821d644d338422ba7f19de612dd060d schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 N98f6d54d1fe840ad9c0833ef1742d009 rdf:first sg:person.01216450244.20
136 rdf:rest N5df8cba9a77c43b9b368dc9b4dfcc62a
137 Nb50a77bf61fc48af9e11d78aac6fb584 schema:affiliation grid-institutes:grid.418567.9
138 schema:familyName Matsui
139 schema:givenName Akiko
140 rdf:type schema:Person
141 Nf194eba3b8cf403caa332cd24fe420dd rdf:first Nb50a77bf61fc48af9e11d78aac6fb584
142 rdf:rest N1e253898ee91435aaa27584882508958
143 Nf973524fc7ac4f08b290c7052d5c20a1 rdf:first sg:person.0736342751.97
144 rdf:rest N98f6d54d1fe840ad9c0833ef1742d009
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
149 schema:name Clinical Sciences
150 rdf:type schema:DefinedTerm
151 sg:journal.1051855 schema:issn 2198-9788
152 2199-1154
153 schema:name Drugs - Real World Outcomes
154 schema:publisher Springer Nature
155 rdf:type schema:Periodical
156 sg:person.01216450244.20 schema:affiliation grid-institutes:grid.418567.9
157 schema:familyName Fujimoto
158 schema:givenName Yoko
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216450244.20
160 rdf:type schema:Person
161 sg:person.01257511361.01 schema:affiliation grid-institutes:grid.265107.7
162 schema:familyName Inagaki
163 schema:givenName Yoshimi
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257511361.01
165 rdf:type schema:Person
166 sg:person.0736342751.97 schema:affiliation grid-institutes:None
167 schema:familyName Laurent
168 schema:givenName Thomas
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736342751.97
170 rdf:type schema:Person
171 sg:pub.10.1007/s00134-002-1338-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1002941822
172 https://doi.org/10.1007/s00134-002-1338-y
173 rdf:type schema:CreativeWork
174 sg:pub.10.1186/cc712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051258507
175 https://doi.org/10.1186/cc712
176 rdf:type schema:CreativeWork
177 grid-institutes:None schema:alternateName Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan
178 schema:name Clinical Study Support, Inc, Daiei Bldg., 2F, 1-11-20 Nishiki, Naka-ku, Nagoya, Aichi 460-0003 Japan
179 rdf:type schema:Organization
180 grid-institutes:grid.265107.7 schema:alternateName Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan
181 schema:name Division of Anesthesiology and Clinical Care Medicine, Department of Surgery, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago, Tottori 683-8503 Japan
182 rdf:type schema:Organization
183 grid-institutes:grid.418567.9 schema:alternateName Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan
184 schema:name Medical Affairs, Pfizer Essential Heath, Pfizer Japan, Inc, Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Sibuya-ku, Tokyo, 151-8589 Japan
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...